author
contribut
equal
work
one
sentenc
summari
antiarrhythm
drug
amiodaron
one
activ
metabolit
interfer
earli
step
ebola
viru
life
cycl
block
fusion
step
viral
envelop
endosom
membran
ebola
viru
diseas
evd
one
lethal
transmiss
infect
character
high
fatal
rate
treatment
develop
yet
recent
shown
cation
amphiphil
among
antiarrhythm
drug
amiodaron
inhibit
filoviru
infect
present
work
investig
amiodaron
interfer
ebola
viru
infect
wildtyp
sudan
ebolaviru
recombin
vesicular
stomat
viru
pseudotyp
zair
ebolaviru
glycoprotein
use
gain
insight
abil
amiodaron
affect
ebola
viru
infect
show
amiodaron
decreas
ebola
viru
infect
concentr
close
found
sera
patient
treat
arrhythmia
drug
act
interf
fusion
viral
envelop
endosom
membran
also
show
mdea
main
amiodaron
metabolit
contribut
antivir
activ
final
studi
amiodaron
analogu
indic
antivir
activ
correl
drug
abil
accumul
interfer
endocyt
pathway
consid
well
toler
especi
acut
set
amiodaron
appear
deserv
consider
clinic
use
evd
ebola
viru
diseas
evd
diseas
human
nonhuman
primat
caus
five
genet
distinct
member
ebolaviru
genu
filovirida
famili
far
zair
sudan
bundibugyo
virus
respons
human
evd
outbreak
feldmann
geisbert
ebola
viru
ebov
infect
broad
rang
cell
type
feldmann
geisbert
bind
entri
target
cell
mediat
viral
glycoprotein
gp
class
fusion
protein
compos
receptor
bind
subunit
fusion
subunit
lee
et
al
lee
saphir
initi
intern
via
macropinocytosi
viru
particl
traffick
endolysosom
pathway
end
late
endosom
lowphdepend
cystein
proteas
cathepsin
b
l
allow
process
kda
fusogen
form
chandran
et
al
schornberg
et
al
dube
et
al
hood
et
al
miller
et
al
subsequ
interact
process
late
endosomallysosom
protein
neimannpick
lead
fusion
viral
envelop
limit
membran
endosom
carett
et
al
cote
et
al
miller
et
al
protein
necessari
viru
infect
cell
patient
neimannpick
diseas
due
lack
malfunct
protein
resist
ebov
infect
carett
et
al
addit
recent
demonstr
ebov
entri
target
cell
requir
also
presenc
endosomallysosom
calcium
channel
call
twopor
channel
sakurai
et
al
multipl
cation
amphiphil
report
inhibit
ebov
infect
carett
et
al
johansen
et
al
shoemak
et
al
particular
shown
antiarrhythm
drug
amiodaron
dronedaron
multiion
channel
inhibitor
inhibit
filoviru
infect
act
earli
step
viral
life
cycl
gehr
et
al
interestingli
amiodaron
dronedaron
induc
npclike
phenotyp
sever
cell
type
morissett
et
al
piccoli
et
al
found
amiodaron
inhibit
fusion
zair
ebolaviru
glycoprotein
zebov
gp
endosom
membran
ii
amiodaron
main
metabolit
monodesethyl
amiodaron
mdea
potent
inhibit
sudan
ebolaviru
sudv
entri
progeni
releas
infect
cell
iii
antivir
activ
correl
amiodaron
abil
induc
npclike
phenotyp
sinc
effect
observ
concentr
close
found
sera
patient
treat
arrhythmia
appear
amiodaron
could
attract
candid
treatment
evd
human
embryon
kidney
cell
african
green
monkey
kidney
vero
cell
grown
c
co
dulbecco
modifi
eagl
medium
life
technolog
supplement
heatinactiv
foetal
bovin
serum
life
technolog
plasmid
express
zebov
gp
kindli
provid
gari
nabel
vaccin
research
center
nih
bethesda
usa
plasmid
express
vesicular
stomat
viru
vsv
glycoprotein
pvsvg
previous
describ
salata
et
al
amiodaron
purchas
sigmaaldrich
dronedaron
extract
multaq
pill
sanofiaventi
previous
describ
piccoli
et
al
synthesi
characterist
amiodaron
analogu
fig
previous
report
quaglino
et
al
ha
et
al
recombin
vsv
contain
gene
encod
green
fluoresc
protein
place
vsvg
gene
vsv
ggfp
provid
michael
whitt
univers
tennesse
usa
zebov
gp
pseudotyp
vsv
ggfp
gppseudotyp
viru
gener
previous
describ
whitt
briefli
cell
transfect
lipofectamin
life
technolog
plasmid
infect
recombin
vsv
ggfp
viru
multipl
infect
moi
fluoresc
focusform
unit
ffu
cell
h
viru
harvest
store
c
viral
titer
evalu
cytofluorimetr
analysi
facscalibur
becton
dickinson
vero
cell
infect
limit
dilut
viral
stock
data
analys
cellquest
softwar
antivir
activ
assay
vero
cell
expos
appropri
compound
time
indic
next
cell
infect
recombin
virus
moi
ffucel
h
later
gfpposit
cell
evalu
infect
sudv
perform
ad
viru
moi
ffucel
vero
cell
one
hour
later
unbound
viru
remov
fresh
medium
appropri
compound
ad
h
cell
fix
icecold
methanolaceton
c
min
cell
process
immunofluoresc
use
antibodi
target
viral
nucleoprotein
previous
describ
weidmann
et
al
viral
progeni
releas
evalu
supernat
collect
h
postinfect
immunostain
infect
vero
cell
experi
sudv
perform
biosafeti
level
laboratori
public
health
agenc
sweden
solna
sweden
vero
cell
grown
coverslip
kept
control
medium
pretreat
h
either
amiodaron
subsequ
cell
incub
h
gppseudotyp
viru
moi
ffucel
next
cell
fix
min
paraformaldehyd
sigmaaldrich
permeabil
min
triton
sigma
aldrich
vsv
matrix
vsvm
protein
detect
incub
min
c
antibodi
kerafast
inc
alexa
antibodi
life
technolog
cell
counterstain
tm
cell
signal
technolog
visual
nuclei
imag
acquir
use
nikon
confoc
microscop
nikon
instrument
cathepsin
b
substrat
zargargmca
cathepsin
l
substrat
zpheargmca
sigmaaldrich
store
c
mm
dmso
stock
dilut
brij
sigmaaldrich
use
mm
dmso
stock
cathepsin
b
inhibitor
calbiochem
prepar
store
c
concentr
brought
reaction
buffer
use
measur
effect
amiodaron
cathepsin
activ
vero
cell
grown
semiconflu
six
well
plate
three
well
incub
h
amiodaron
three
well
serv
control
end
incub
cell
rins
cold
pb
pool
scrape
two
eppendorf
tube
wash
two
time
cold
pb
lyse
mm
sodium
acet
mm
edta
triton
ph
min
ice
lysat
centrifug
g
min
supernat
store
c
cathepsin
assay
ebert
et
al
perform
use
protein
lysat
substrat
total
volum
combin
reaction
buffer
mm
sodium
acet
mm
edta
mm
dithiothreitol
ph
zargargmca
solut
cathepsin
b
assay
b
reaction
buffer
final
concentr
zpheargmca
cathepsin
l
assay
c
reaction
buffer
zpheargmca
cathepsin
bl
assay
reaction
allow
proceed
h
c
dark
stop
addit
cold
reaction
buffer
fluoresc
measur
use
fluoromet
excit
nm
emiss
nm
data
express
mean
standard
deviat
sd
differ
analys
student
test
level
accept
signific
p
recent
report
amiodaron
inhibit
filoviru
replic
vitro
mechan
inhibit
remain
unclear
gehr
et
al
patient
arrhythmia
chronic
treat
mg
day
amiodaron
drug
plasma
concentr
rang
intraven
administr
plasma
level
increas
ha
et
al
breitenstein
et
al
previous
report
h
incub
amiodaron
induc
fullfledg
npclike
phenotyp
piccoli
et
al
order
confirm
antiebolaviru
activ
amiodaron
analys
whether
npclike
phenotyp
play
role
level
vero
cell
incub
h
amiodaron
previous
display
appreci
cytotox
piccoli
et
al
cell
infect
recombin
vsv
encod
green
fluoresc
protein
gfp
place
glycoprotein
g
vsv
ggfp
pseudotyp
either
envelop
glycoprotein
g
vsv
vsvrecombin
viru
zebovenvelop
glycoprotein
gppseudotyp
viru
moi
ffucel
employ
achiev
percentag
infect
cell
allow
recombin
virus
test
evalu
antivir
effect
without
satur
system
two
hour
postinfect
cell
rins
incub
addit
h
presenc
appropri
drug
concentr
evalu
gfpposit
cell
cytofluorimetri
h
time
frame
select
order
ensur
adhes
target
cell
use
recombin
virus
adopt
experiment
set
result
show
amiodaron
inhibit
gppseudotyp
viru
dosedepend
manner
estim
ic
half
maxim
dose
inhibitori
concentr
fig
contrast
drug
display
effect
vsvrecombin
viru
next
dissect
mechan
amiodaron
inhibit
infect
gppseudotyp
viru
moi
ffucel
incub
vero
cell
untreat
drug
expos
amiodaron
h
infect
viral
adhes
adhes
fig
cell
fluoresc
measur
found
signific
reduct
gfpposit
cell
amiodaron
pretreat
amiodaron
present
viral
adhes
limit
effect
observ
amiodaron
ad
viral
adhes
result
suggest
amiodaron
could
interfer
infect
direct
effect
viral
entri
induct
npclike
phenotyp
find
confirm
experiment
set
sudv
use
infect
vero
cell
moi
ffucel
either
untreat
drug
treat
amiodaron
h
h
infect
h
viral
adhes
h
adhes
adhes
ie
immedi
h
postvir
adhes
fig
cell
analys
immunofluoresc
sudv
infect
significantli
inhibit
condit
fig
furthermor
inhibit
also
achiev
condit
treatment
perform
adhes
caus
inhibit
fig
howev
drug
ad
adhes
step
effect
amiodaron
smaller
especi
drug
ad
h
delay
fig
furthermor
amiodaron
effect
stronger
one
observ
presenc
compound
known
block
fusion
ebov
envelop
endosom
membran
carett
et
al
shoemak
et
al
mdea
main
metabolit
amiodaron
reach
plasma
concentr
close
parent
drug
contribut
antiarrhythm
activ
toxic
quaglino
et
al
ha
et
al
piccoli
et
al
investig
whether
mdea
affect
ebov
entri
vero
cell
incub
h
amiodaron
mdea
combin
amiodaron
mdea
common
condit
patient
take
amiodaron
chronic
next
cell
infect
gppseudotyp
viru
moi
ffucel
h
later
infect
evalu
cytofluorimetri
amiodaron
inhibit
gppseudotyp
viru
infect
effici
mdea
combin
amiodaron
mdea
stronger
inhibitori
effect
one
achiev
treatment
compound
alon
fig
evalu
effect
amiodaronemdea
combin
ebov
infect
employ
sudv
moi
ffucel
twentyfour
h
later
viral
entri
evalu
indirect
immunofluoresc
progeni
releas
test
viral
titrat
h
dronedaron
also
includ
particular
dronedaron
use
concentr
found
patient
chronic
treat
oral
rout
result
show
amiodaron
mdea
combin
inhibit
viral
entri
progeni
releas
effect
stronger
one
due
dronedaron
fig
c
conclud
amiodaron
mdea
concentr
clinic
signific
inhibit
ebov
infect
sinc
data
demonstr
amiodaron
effect
earli
phase
ebolaviru
replic
focus
attent
key
step
viral
envelopeendosom
membran
fusion
vero
cell
treat
h
amiodaron
incub
h
gppseudotyp
viru
vsvrecombin
viru
control
moi
ffucel
next
cell
fix
stain
antivsvm
antibodi
carett
et
al
shown
fig
untreat
cell
display
diffus
cytoplasmat
stain
gppseudotyp
vsvrecombin
virus
indic
fusion
viral
envelop
endosom
membran
occur
allow
releas
vsvm
protein
cytoplasm
contrast
presenc
amiodaron
cell
infect
vsvrecombin
viru
diffus
stain
observ
cell
infect
gppseudotyp
viru
display
punctat
stain
fig
similar
result
also
observ
cell
treat
amiodaron
h
viral
incub
data
shown
amiodaron
mdea
inhibit
gpdepend
entri
vero
cell
treat
h
amiodaron
mdea
infect
h
gppseudotyp
viru
moi
ffucel
afterward
cell
expos
concentr
compound
addit
h
evalu
cytofluorimetri
data
mean
sd
n
experi
conduct
duplic
percentag
gfpposit
cell
respect
drug
set
b
effect
amiodaron
mdea
dronedaron
sudv
entri
vero
cell
treat
h
amiodaron
amiodaron
mdea
dronedaron
infect
sudv
h
moi
ffucel
afterward
cell
expos
concentr
compound
h
viral
entri
evalu
immunostain
sudv
nucleoprotein
specif
antibodi
c
evalu
infecti
viral
particl
releas
vero
cell
treat
h
amiodaron
amiodaron
mdea
dronedaron
infect
sudv
report
cell
expos
h
concentr
compound
next
viral
particl
releas
supernat
titrat
infect
vero
cell
count
sudv
nucleoproteinposit
cell
fluoresc
microscopi
data
b
c
mean
sd
n
experi
duplic
percentag
drug
set
p
h
amiodaron
lyse
cathepsin
activ
measur
cell
lysat
data
mean
sd
present
percentag
cat
b
cat
l
measur
absenc
drug
drug
b
vitro
proteolysi
gp
rescu
viral
infect
vero
cell
treat
h
amiodaron
incub
h
gppseudotyp
viru
moi
ffucel
treat
h
either
reaction
buffer
alon
mock
preactiv
mg
ml
thermolysin
preactiv
cell
incub
h
plain
medium
drug
amiodaron
gfpposit
cell
estim
cytofluorimetri
data
mean
sd
n
experi
duplic
percentag
gfpposit
cell
respect
cell
expos
mock
preactiv
viru
absenc
amiodaron
set
p
viral
entri
virionassoci
gp
process
cathepsin
b
l
kda
fusogen
form
martinez
et
al
although
amiodaron
modifi
total
cell
content
cathepsin
b
l
fig
incub
gppseudotyp
viru
thermolysin
infect
treatment
allow
vitro
process
kda
form
clearli
rescu
viral
infect
fig
overal
data
suggest
amiodaron
affect
gpdriven
fusion
clarifi
structur
basi
amiodaron
abil
interfer
ebov
infect
analys
effect
amiodaron
analogu
fig
gppseudotyp
viru
infect
analogu
alreadi
test
toxic
abil
induc
npclike
phenotyp
quaglino
et
al
bigler
et
al
piccoli
et
al
vero
cell
treat
h
amiodaron
analogu
concentr
clinic
relev
applic
one
suffici
induc
npclike
phenotyp
without
toxic
cell
incub
h
gppseudotyp
viru
moi
ffucel
infect
cell
maintain
medium
contain
appropri
compound
addit
h
gfpposit
cell
evalu
cytofluorimetri
shown
fig
later
group
determin
accumul
acid
organel
requir
antivir
activ
furthermor
appear
among
compound
bear
group
antivir
activ
correl
abil
induc
npclike
phenotyp
meami
amiodaron
pipam
mdea
piccoli
et
al
addit
bulki
benzofuran
hydrophob
moieti
necessari
antivir
activ
group
lack
hydrophob
moieti
inact
note
amiodaron
metabolit
didesethyl
amiodaron
ddea
usual
found
trace
serum
devoid
antivir
activ
overal
antivir
activ
amiodaron
seem
correl
motif
lead
expand
lysosom
phenotyp
logan
et
al
name
presenc
amin
group
amphiphil
bulki
hydrophob
moieti
abil
incorpor
membran
mitterreit
et
al
also
appear
subtl
chang
alkyl
group
chain
meami
compound
might
increas
amiodaron
antivir
effect
evd
one
lethal
transmiss
infect
although
past
diseas
appear
sporad
increas
human
incurs
endem
region
higher
mobil
turn
ebov
highprior
public
threat
sadli
confirm
biggest
epidem
outbreak
ever
current
occur
western
africa
cdc
fast
track
access
treatment
option
evd
key
prioriti
world
health
organ
worstev
outbreak
ebola
rage
west
africa
conclud
ethic
use
unproven
drug
vaccin
tri
combat
diseas
howev
medicin
far
approv
routin
use
evd
current
despit
fact
differ
antiebov
compound
report
literatur
antivir
efficaci
evalu
vitro
anim
model
basu
et
al
cote
et
al
iversen
et
al
johansen
et
al
madrid
et
al
shoemak
et
al
elshabrawi
et
al
gehr
et
al
oestereich
et
al
picazo
giordanetto
warren
et
al
even
though
compound
alreadi
approv
treatment
human
diseas
johansen
et
al
shoemak
et
al
gehr
et
al
clinic
trial
evalu
safeti
efficaci
evd
complet
far
respect
identif
commerci
avail
drug
alreadi
approv
use
human
activ
ebov
might
acceler
organ
clinic
trial
eventu
clinic
use
recent
gehr
et
al
demonstr
amiodaron
dronedaron
drug
approv
treatment
cardiac
arrhythmia
inhibit
filoviru
infect
aim
present
work
character
effect
amiodaron
ebov
infect
interestingli
found
amiodaron
inhibit
ebov
infect
dosedepend
manner
concentr
compar
plasma
level
found
intraven
treat
patient
ic
amiodaron
calcul
employ
recombin
gppseudotyp
vsv
vero
cell
mention
recent
studi
gehr
et
al
report
ic
amiodaron
around
gppseudotyp
lentiviru
around
zebov
take
account
differ
viralcellular
system
employ
overal
data
indic
amiodaron
effici
inhibit
ebov
infect
antivir
potenc
vari
time
cell
exposur
drug
inhibit
maximum
amiodaron
pretreat
induc
npclike
phenotyp
partial
inhibit
also
appreci
amiodaron
ad
earli
step
infect
suggest
antiebov
properti
might
deriv
one
side
cell
structur
modif
associ
amiodaron
accumul
side
direct
effect
drug
specif
step
viral
life
cycl
respect
amiodaron
could
act
modifi
lipid
fluiditi
chatelain
laruel
gillard
increas
membraneproxim
ph
mitterreit
et
al
compet
neg
charg
group
surfac
affect
calcium
channel
requir
matur
endosom
andor
viral
entri
kolter
sandhoff
gehr
et
al
interestingli
found
amiodaron
affect
viral
fusion
previous
report
inhibitor
carett
et
al
viral
intern
gp
cleavag
proce
kda
intermedi
ultim
gener
key
kda
core
protein
chandran
et
al
schornberg
et
al
dube
et
al
hood
et
al
miller
et
al
interestingli
artifici
activ
gp
thermolysin
treatment
viral
particl
infect
rescu
effect
amiodaron
demonstr
amiodaron
affect
stabil
specif
protein
spa
baritussio
et
al
demonstr
cellular
content
cathepsin
b
l
requir
format
fusogen
form
gp
affect
drug
treatment
howev
exclud
amiodaron
might
influenc
activ
proteas
demonstr
differ
proteolyt
enzym
mitterreit
et
al
piccoli
et
al
furthermor
specif
effect
step
subsequ
ebov
entryfus
demonstr
case
sar
coronaviru
hcv
stadler
et
al
cheng
et
al
rule
importantli
found
addit
effect
amiodaron
pharmacolog
activ
metabolit
mdea
gpmediat
entri
target
cell
furthermor
result
show
concentr
clinic
interest
amiodaron
amiodaronemdea
combin
effect
dronedaron
reduc
sudv
infect
final
found
presenc
tertiari
amin
compound
play
key
role
antivir
effect
demonstr
use
differ
amiodaron
deriv
antifiloviru
activ
addit
amphiphil
cation
johansen
et
al
shoemak
et
al
moreov
hydrophob
moieti
also
critic
perhap
regul
interact
membran
overal
observ
support
idea
antivir
activ
amiodaron
reli
abil
interact
membran
accumul
acid
organel
logan
et
al
induc
npclike
phenotyp
piccoli
et
al
shoemak
et
al
gehr
et
al
conclus
demonstr
antiarrhythm
drug
amiodaron
specif
interfer
earli
step
ebov
life
cycl
thu
block
viral
replic
overal
data
provid
evid
amiodaron
deserv
seriou
consider
treatment
evd
